Sarepta Therapeutics Inc SRPT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SRPT is a good fit for your portfolio.
News
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sarepta Therapeutics' stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug
-
Sarepta Shares Soar 37% Following Expanded Approval for Elevidys
-
Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above
-
Pfizer's gene-therapy trial failure boosts Sarepta's stock
-
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sarepta Therapeutics Set to Join S&P MidCap 400
-
Gene Therapy Pioneer Jerry R. Mendell, M.D., Named to Inaugural TIME100 Health List of the 100 Most Influential People in Global Health
Trading Information
- Previous Close Price
- $153.11
- Day Range
- $150.98–152.58
- 52-Week Range
- $55.25–173.25
- Bid/Ask
- $151.65 / $151.95
- Market Cap
- $14.34 Bil
- Volume/Avg
- 961,922 / 1.8 Mil
Key Statistics
- Price/Earnings (Normalized)
- 141.82
- Price/Sales
- 10.29
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Mid Growth
- Total Number of Employees
- 1,314
- Website
- https://www.sarepta.com
Comparables
Valuation
Metric
|
SRPT
|
MRNA
|
RARE
|
---|---|---|---|
Price/Earnings (Normalized) | 141.82 | — | — |
Price/Book Value | 14.92 | 3.54 | 24.22 |
Price/Sales | 10.29 | 8.87 | 7.11 |
Price/Cash Flow | 97.55 | — | — |
Price/Earnings
SRPT
MRNA
RARE
Financial Strength
Metric
|
SRPT
|
MRNA
|
RARE
|
---|---|---|---|
Quick Ratio | 2.97 | 3.74 | 2.09 |
Current Ratio | 4.05 | 4.03 | 2.43 |
Interest Coverage | −1.00 | −148.54 | −8.73 |
Quick Ratio
SRPT
MRNA
RARE
Profitability
Metric
|
SRPT
|
MRNA
|
RARE
|
---|---|---|---|
Return on Assets (Normalized) | 6.50% | −28.15% | −35.51% |
Return on Equity (Normalized) | 25.41% | −37.30% | −299.94% |
Return on Invested Capital (Normalized) | 7.51% | −36.39% | −224.67% |
Return on Assets
SRPT
MRNA
RARE
Biotechnology Industry Comparables
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
---|---|---|---|---|---|---|
Novo Nordisk A/S ADR
NVO
| Hmqgzzvn | Wpmrd | $628.7 Bil | |||
Vertex Pharmaceuticals Inc
VRTX
| Lhtxxbx | Lsrckwf | $121.4 Bil | |||
Regeneron Pharmaceuticals Inc
REGN
| Yhxhlkzk | Pckzdmp | $114.0 Bil | |||
Moderna Inc
MRNA
| Pzhjxnwh | Rzc | $45.3 Bil | |||
Alnylam Pharmaceuticals Inc
ALNY
| Cspyjmnlk | Zkklwd | $31.5 Bil | |||
argenx SE ADR
ARGX
| Pslkyfjm | Kmgld | $25.9 Bil | |||
BioNTech SE ADR
BNTX
| Vqjvjtm | Cfzn | $19.2 Bil | |||
Biomarin Pharmaceutical Inc
BMRN
| Thgblhtz | Dbpdzq | $15.4 Bil | |||
United Therapeutics Corp
UTHR
| Prgrhfdtj | Nvfw | $14.0 Bil | |||
Royalty Pharma PLC Class A
RPRX
| Rmcygrdly | Clpgsx | $11.7 Bil |